three-day treatment period; and a second study will compare CDA to Lapdap alone. If the development of CDA is successful, it is expected to be available in 2008 as a convenient, once-daily dose. CDA will be made available to the public sector of malaria-endemic countries at preferential prices in order to maximise its availability to those in need.
CDA is being developed in collaboration with GlaxoSmithKline (GSK), the World Health Organization's Special Programme for Research and Training in Tropical Diseases (WHO/TDR), Medicines for Malaria Venture (MMV), the University of Liverpool, Liverpool School of Tropical Medicine and the London School of Hygiene & Tropical Medicine.
Dr. Robert Ridley, Director of WHO/TDR, stated, "The collaboration between WHO/TDR, MMV, GSK and our academic partners has enabled us to combine resources and expertise to speed the development of CDA."
"GSK is committed to research and development into treatments for diseases of the developing world," said Dr. Lynn Marks, Senior Vice President, Infectious Diseases Medicine Development Centre for GSK. "Public-private partnerships, such as this one for CDA, are vital in ensuring that urgently needed medicines are made available as quickly and safely as possible."
Page: 1 2 Related biology news :1
. Cost-effectiveness study of three antimalarial drug combinations in Tanzania2
. Research milestone brings goal closer of cheap antimalarial drug for developing world3
. $43 million from Gates Foundation to produce inexpensive antimalarial drug for Third World4
. Cetuximab and irinotecan combination increases survival in metastatic colorectal cancer5
. New study suggests promising drug combinations for sleeping sickness6
. Recombination protein dynamics observed with single monomer resolution7
. AVELOX as effective as multi-dose combination therapy for intra-abdominal infections8
. New combination treatment induces regression of prostate cancer9
. Avelox as effective as Levofloxacin combination therapy for severe community-acquired pneumonia10
. New observational study suggests use of combination vaccines may improve immunization coverage rates in infants11
. Pesticide combinations imperil frogs, probably contribute to amphibian decline